


Stephen Grobmyer
429 posts

@grobmys












HER3-targeted patritumab deruxtecan showed efficacy in leptomeningeal metastases from solid tumors in the Phase II TUXEDO-3 trial 📈 65% 3-month survival 🧬 Activity in intracranial lesions 🔷 From Matthias Preusser, MD, et al in @NatureMedicine 🔗 ascopost.com/news/july-2025…



From diagnosis and 'tumor board' meetings, to treatment, #ClevelandClinicAbuDhabi comprehensive Lung Cancer Program is the most advanced in the region, with a course of action for every scenario. So let’s walk you through it now. Watch the full video to learn more.




An Editor's Pick paper at @jbiolchem! Don't forget to read the profile about the first author @li_xiuxiu_ at the end of our paper on HSD3B1 and breast cancer! Dr. Li recently moved from @dsui_miami_uro and @SylvesterCancer to @ONealCancerUAB sciencedirect.com/science/articl…
















